Industry recognition. See more on the awards page.
At ICON, we are at the forefront of innovation in clinical research, harnessing the power of Artificial Intelligence to transform the way trials are conducted.
Our AI solutions are designed to accelerate trial timelines, improve data accuracy, optimise resource management, and ensure compliance—all while maintaining the highest ethical standards. With our AI-driven approach, we are committed to delivering faster, smarter, and more reliable outcomes that benefit sponsors, patients, and healthcare providers for a healthier world.
AI champions
Our AI literacy program and network of AI Champions identify areas for greater efficiencies within the organisation.
Data scientists and engineers
Data scientists and engineers drive robust strategies, testing, development and impactful solutions.
Award-winning solutions
Multi-award winning innovative and pragmatic solutions delivering measurable and impactful value to our clients.
Our AI solutions
To provide a comprehensive understanding of our AI capabilities, we ve categorised our solutions into three main areas.
Accelerating trial execution
Our solutions in this category focus on streamlining the clinical trial process, from site selection to patient enrolment and study startup. These tools significantly reduce trial timelines and improve overall trial performance.
One Search
Identify the right sites and investigators faster, reducing time to site identification and improving patient recruitment success rates.
ICONex
Quickly identify key opinion leaders in all therapeutic areas including rare diseases, accelerating study design and startup.
Cassandra
Predict post-marketing study requirements early, allowing for proactive planning and reducing the risk of regulatory delays.
Enhancing data and resource management
These solutions are designed to improve the quality and efficiency of data management and resource allocation, ensuring that clinical trials run smoothly and effectively.
iSubmit
Automate document management for clinical trials, ensuring compliance and reducing the burden on study teams.
MRT COA
Stay updated with the latest clinical outcome assessments, providing comprehensive intelligence to optimise trial designs.
FORWARD+
Optimise your resource management with precise forecasting, targeted information and seamless automation.
Optimising operational efficiency
Our operational efficiency solutions are designed to transform the way teams interact with data and streamline critical processes, leading to faster and more informed decision making.
SmartDraft
Use AI to streamline site contract drafting, reduce negotiation cycles and accelerate site activation.
OMR AI Navigation Assistant
Gain quick, actionable insights from complex operational metrics with AI powered natural language queries.
Why choose AI at ICON?
-
proven results
Our AI solutions have been recognised with industry awards and have consistently delivered measurable improvements in trial performance. -
governance
We prioritise responsible AI use, backed by our AI Ethics Committee, ensuring that our solutions adhere to the highest standards of data privacy and security. -
innovation
We are continually pushing the boundaries of what's possible in clinical research to make trials more efficient, safe and insightful.
AI ethics committee
Our AI ethics committee ensures ICON is fully compliant and that we act ethically and with integrity. We will continue to provide the highest standard of data quality and protect and preserve our stakeholders’ individual privacy, confidentiality, and intellectual property rights.
AI at ICON insights and media contributions
Featured whitepapers
Integrating AI into clinical research: How AI is being used to enhance clinical development
AI is transforming clinical research – making drug development faster, more efficient, and more precise. ICON’s latest whitepaper explores how AI is already being integrated into clinical operations, featuring insights from the 2024 Citeline Survey and global research from Tufts CSDD and DIA.
Digital Disruption: Surveying the industry’s evolving landscape
The clinical research industry is embracing innovation to enhance safety, efficiency, and R&D returns, but digital disruption is progressing slower than expected. Our whitepaper analyses survey findings alongside 2019 results to uncover key factors influencing the adoption of advanced technologies like big data and AI.
Advancements in Artificial Intelligence for site selection
By harnessing the combined power of human expertise and AI technology, One Search delivers significant improvements across all key metrics, including recruitment rates, site identification speed, and compliance with project timelines.
.jpg?crop=yes&w=1430&h=750&a=5,0&itok=k-Z-uNPO "whitepaper_navigating real world healthcare data integr_thumbnail_Home Page Banner 1440 x 750 (1)"){kind=icon}
Beyond the token: Why real-world healthcare data and integration strategy matters
This whitepaper explores the challenges and opportunities arising from the proliferation of healthcare data, emphasising the need for robust data integration strategies to leverage this data effectively.
Applying AI to manage the risks and costs of postmarketing requirements
Our Cassandra AI system harnesses RWD on drugs and data obtained from the US FDA and EMA postmarketing requirements databases to accurately forecast whether postmarketing studies will be necessary.
-
Media article: Harnessing AI and big data in clinical research
The article explores the evolving role of AI and digital technologies in clinical research, highlighting industry trends, adoption challenges, and the potential for improved efficiency, cost reduction, and accelerated drug development.
-
Media article: AI, Big Data, and Digital Disruption
This article takes a look at ICON's recent digital disruption survey which surveys changing attitudes and challenges in digital innovation for clinical research.
-
Media article: AI superintelligence startup promises new drug discoveries
This article by Greg Licholai discusses how AI is revolutionising drug discovery, with companies like Lila Sciences and Recursion Pharmaceuticals leading the charge by using AI to accelerate scientific breakthroughs. Lila focuses on creating "scientific superintelligence" through autonomous labs, while Recursion maps human biology to discover new treatments faster.
-
Media article: ICON discusses how AI is changing clinical trial recruitment and diversity
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
-
Blog: A clinical trial linguist’s perspective on machine translation
Perspectives on what machine translation means for clinical trial translations from an experienced clinical trial linguist.
-
Media article: AI-powered precision measures: A golden opportunity for clinical research
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce operational efficiencies. AI-powered digital measures are being developed and validated to better define disease, patients, and drug efficacy.
-
Media article: AI’s transformative role in drug discovery and development
In the Irish Times Life Sciences and Stem supplement, ICON’s CIO Tom O’Leary discussed AI is transforming drug development across a range of specific use cases, from discovery to clinical trials and post-marketing.
-
Media article: How AI can manage the risks and costs of postmarketing requirements
Postmarketing requirements (PMRs) for drug development are commonly required to gather data on a product’s longer-term safety, efficacy and optimal use. Carefully applied AI and machine learning offers the potential for better management of PMRs.
Get started with AI at ICON
Ready to transform your clinical trials with AI? Contact us today to learn how ICON's AI solutions can accelerate your research and deliver better outcomes.